Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
Data updated
Papers
Trials
Research Footprint
Anna Forsyth appears in 8 tracked papers (2020–2026), most studied alongside LSD, Ketamine and MDMA, across Microdosing, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. (82 citations).
Frequent co-authors: Suresh Muthukumaraswamy, Rebecca Sumner and Frederick Sundram.
Background & Research
Anna Forsyth is a researcher associated with the University of Auckland’s Faculty of Medical and Health Sciences. Her work has appeared on clinical and translational studies involving LSD microdosing, including trials in major depressive disorder, healthy-volunteer mood effects, sleep outcomes, and related psychedelic psychiatry publications. Available records also connect her with neuroimaging and pharmacology research at the university.
Key Impact
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Anna Forsyth is associated with.
University of Auckland
The University of Auckland hosts academic psychedelic research activity, including work led by Professor Suresh Muthukumaraswamy on LSD microdosing and related mental health applications.
View stakeholder →University of Wisconsin–Madison School of Pharmacy
The University of Wisconsin–Madison School of Pharmacy is the pharmacy school of the public research university UW–Madison, located in Madison, Wisconsin. It offers professional (PharmD), graduate and research programs in pharmaceutical sciences, clinical pharmacy, and related fields.
View stakeholder →